A-1 (542012)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Positive net profit of ₹1 Cr in the latest quarter, albeit razor-thin
• ROCE of 10.63% is positive and suggests some operating efficiency
• Quarterly sales of ₹70 Cr show a functioning business with meaningful scale

Concerns

• P/E of 470.06 and P/B of 268.71 imply extreme overvaluation with no margin of safety
• Sales growth of -6.08% and profit growth of -4.00% show a shrinking business
• ROE of 5.17% and Piotroski F-Score of 3/9 signal weak fundamental health
• Dividend yield of 0.15% provides virtually no income cushion

AI Analysis

At ₹343.95, Mr. Market is asking me to pay ₹398 crore for a chemical trading business that earned just ₹1 crore in the latest quarter—and roughly ₹0.85 crore over the year, working backwards from a P/E of 470. That is not a price; it is a hope. Book value is ₹1.28 per share, so the P/B of 268.71 means I pay ₹269 for every rupee of net worth. Graham would call this speculation, not investment. The 52-week range from ₹9.22 to ₹482.05 tells me this stock is a trading vehicle, not a compounding asset. Fundamentals are poor: sales fell 6.08%, profits fell 4%, and return on equity is just 5.17%. The Piotroski F-Score of 3/9 hints at deteriorating financial health. Positive ROCE of 10.63% is the only bright spot, but with such a thin equity base and a low-margin trading business, it offers no durable advantage. Dividend yield of 0.15% is negligible. Chemical trading has no pricing power, no moat, and earnings fluctuate with input costs and demand. There is no margin of safety at this valuation. The stock may continue to swing, but I cannot value it with any confidence when the underlying business earns so little. My rule is simple: be fearful when others are greedy. Here, there is extreme greed at 470 times earnings. I will watch from the sidelines and wait for a price that reflects the minuscule earnings and poor returns. Until then, this belongs in the 'too hard' pile.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer